OBJECTIVES: GLP-1 agonists in combination with basal insulin (BI) have demonstrated additional improvement of glycemic control in uncontrolled T2DM patients in clinical trials.  It is therefore important to assess the real-world utilisation of GLP-1 agonists in combination with BI in T2DM patients. METHODS: Retrospective cohort analysis (2010 to 2012) to assess GLP-1 agonist utilisation in T2DM patients based on the Norwegian Institute of Public Health Prescription Database (NorPD).  Both ICPC=T90 and ICD-10=E11 were applied to identify T2DM patients. Patients who had ≥2 GLP-1 dispensed within 6-month in Year-2011, with 1-year pre-Baseline/post- Follow-up GLP-1 initiation were included in the analysis.  Baseline anti-diabetic drug use and combination use of GLP-1 and BI at Follow-up were also assessed. RESULTS: Of the 1,500 GLP-1 initiators identified (mean age=57; 52% male) at Baseline,  77% were on OADs, 19% on BI, 2% on prandial insulin (no BI) and 2% on other/no anti-diabetic drug.  During 1-year Follow-up of GLP-1 adding on OADs patient population, 56% used GLP-1 continuously including 50% who used GLP-1 alone and 6% added BI. In total, 15% had either combined with or switched to BI, 4 months after the first GLP-1 was dispensed. Of those GLP-adding on BI patient population, 53% continuously used GLP-1 including 26% had both GLP-1 and BI dispensed throughout the Follow-up.  About 52% had either BI interrupted or discontinued approximately 2 months after the 1st GLP-1 was dispensed.  In total, 27% had insulin bolus dispensed; of which 58% either interrupted or discontinued GLP-1. CONCLUSIONS: About 1/3 of GLP-1 initiators were in combination with BI. In BI treated T2DM patients >25% remained on both GLP-1 and BI, while another >25% required treatment augmentation or switched to bolus.  The data suggests an unmet treatment need, particularly in T2DM patients treated with BI.